{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:22:33Z","timestamp":1788452553715,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02223-w","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:36:14Z","timestamp":1769171774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic accuracy of FDG-PET-CT to predict axillary lymph node response after neo-adjuvant chemotherapy in lymph node-positive breast cancer patients"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-2911","authenticated-orcid":false,"given":"Kiran Kasper","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni J.","family":"Nijveldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper H. G.","family":"Helthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M. A.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Vendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.","family":"Nijholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"van\u2019t Veer-ten Kate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"van der Starre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van der Steeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schelto","family":"Kruijff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinus A.","family":"Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Brecht","family":"Francken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2223_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2223_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"key":"2223_CR3","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","volume":"47","author":"X Kong","year":"2011","unstructured":"Kong X, Moran MS, Zhang N, et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011;47:2084\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.014.","journal-title":"Eur J Cancer"},{"key":"2223_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.breast.2013.02.001","volume":"22","author":"W Gatzemeier","year":"2013","unstructured":"Gatzemeier W, Bruce Mann G. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)\u2014ACOSOG Z0011 results and beyond. Breast. 2013;22:211\u20136. https:\/\/doi.org\/10.1016\/j.breast.2013.02.001.","journal-title":"Breast"},{"key":"2223_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10549-010-1210-7","volume":"125","author":"MJ Pepels","year":"2011","unstructured":"Pepels MJ, Vestjens JHMJ, de Boer M, et al. Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat. 2011;125:301\u201313. https:\/\/doi.org\/10.1007\/s10549-010-1210-7.","journal-title":"Breast Cancer Res Treat"},{"key":"2223_CR6","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3390\/cancers13071539","volume":"13","author":"PK Swarnkar","year":"2021","unstructured":"Swarnkar PK, Tayeh S, Michell MJ, Mokbel K. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers. 2021;13:1539. https:\/\/doi.org\/10.3390\/cancers13071539.","journal-title":"Cancers"},{"key":"2223_CR7","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1245\/s10434-024-15182-3","volume":"31","author":"JJ Nijveldt","year":"2024","unstructured":"Nijveldt JJ, Rajan KK, Boersma K, et al. Implementation of the targeted axillary dissection procedure in clinically node-positive breast cancer: a retrospective analysis. Ann Surg Oncol. 2024;31:4477\u201386. https:\/\/doi.org\/10.1245\/s10434-024-15182-3.","journal-title":"Ann Surg Oncol"},{"key":"2223_CR8","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332. https:\/\/doi.org\/10.1007\/s00259-024-06696-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2223_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2024;35:159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"key":"2223_CR10","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.eanmj.2025.100004","volume":"1","author":"SC Vaz","year":"2025","unstructured":"Vaz SC, MacLennan S, van Nijnatten T, et al. European association of nuclear medicine (EANM) focus meeting 6 consensus on molecular imaging in breast cancer (endorsed by EUSOBI, ESSO, ESTRO, EuropaDonna). EANM J. 2025;1:100004. https:\/\/doi.org\/10.1016\/j.eanmj.2025.100004.","journal-title":"EANM J"},{"key":"2223_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","volume":"46","author":"S Han","year":"2021","unstructured":"Han S, Choi JY. Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer: a systematic review and meta-analysis. Clin Nucl Med. 2021;46:271. https:\/\/doi.org\/10.1097\/RLU.0000000000003502.","journal-title":"Clin Nucl Med"},{"key":"2223_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1053\/j.semnuclmed.2022.05.001","volume":"52","author":"D Groheux","year":"2022","unstructured":"Groheux D. FDG-PET\/CT for primary staging and detection of recurrence of breast cancer. Semin Nucl Med. 2022;52:508\u201319. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.001.","journal-title":"Semin Nucl Med"},{"key":"2223_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40336-021-00426-z","volume":"9","author":"D Groheux","year":"2021","unstructured":"Groheux D, Hindie E. Breast cancer: initial workup and staging with FDG PET\/CT. Clin Transl Imaging. 2021;9:221\u201331. https:\/\/doi.org\/10.1007\/s40336-021-00426-z.","journal-title":"Clin Transl Imaging"},{"key":"2223_CR14","unstructured":"Federatie Medisch Specialisten. Borstkanker\u2014Algemeen\u2014Richtlijn\u2014Richtlijnendatabase. 2020. https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/startpagina_-_borstkanker.html. Accessed 20 Jan 2025"},{"key":"2223_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1053\/j.semnuclmed.2022.03.004","volume":"52","author":"MG Hildebrandt","year":"2022","unstructured":"Hildebrandt MG, Naghavi-Behzad M, Vogsen M. A role of FDG-PET\/CT for response evaluation in metastatic breast cancer? Semin Nucl Med. 2022;52:520\u201330. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.03.004.","journal-title":"Semin Nucl Med"},{"key":"2223_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01350-2","volume":"22","author":"S Han","year":"2020","unstructured":"Han S, Choi JY. Prognostic value of 18F-FDG PET and PET\/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2020;22:119. https:\/\/doi.org\/10.1186\/s13058-020-01350-2.","journal-title":"Breast Cancer Res"},{"key":"2223_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40336-023-00584-2","volume":"11","author":"D Groheux","year":"2023","unstructured":"Groheux D, Ulaner GA, Hindie E. Breast cancer: treatment response assessment with FDG-PET\/CT in the neoadjuvant and in the metastatic setting. Clin Transl Imaging. 2023;11:439\u201352. https:\/\/doi.org\/10.1007\/s40336-023-00584-2.","journal-title":"Clin Transl Imaging"},{"key":"2223_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07129-x","author":"F Godard","year":"2025","unstructured":"Godard F, Oosthoek J, Alexis A, et al. Estimation of carbon footprint in nuclear medicine: illustration of a french department. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07129-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2223_CR19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268928","author":"P Veit-Haibach","year":"2025","unstructured":"Veit-Haibach P, Herrmann K, Zimmermann R, Hustinx R. Green nuclear medicine and radiotheranostics. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.268928.","journal-title":"J Nucl Med"},{"key":"2223_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s12282-021-01240-1","volume":"28","author":"E Nagasaki","year":"2021","unstructured":"Nagasaki E, Kudo R, Tamura M, et al. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report. Breast Cancer. 2021;28:1051\u201361. https:\/\/doi.org\/10.1007\/s12282-021-01240-1.","journal-title":"Breast Cancer"},{"key":"2223_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.breast.2022.12.007","volume":"67","author":"A van Ommen-Nijhof","year":"2023","unstructured":"van Ommen-Nijhof A, Steenbruggen TG, Capel L, et al. Survival and prognostic factors in oligometastatic breast cancer. Breast. 2023;67:14\u201320. https:\/\/doi.org\/10.1016\/j.breast.2022.12.007.","journal-title":"Breast"},{"key":"2223_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2223_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-017-0176-5","volume":"4","author":"D Koopman","year":"2017","unstructured":"Koopman D, Groot Koerkamp M, Jager PL, et al. Digital PET compliance to EARL accreditation specifications. EJNMMI Phys. 2017;4:9. https:\/\/doi.org\/10.1186\/s40658-017-0176-5.","journal-title":"EJNMMI Phys"},{"key":"2223_CR24","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","volume":"273","author":"S Samiei","year":"2021","unstructured":"Samiei S, de Mooij CM, Lobbes MBI, et al. Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2021;273:694\u2013700. https:\/\/doi.org\/10.1097\/SLA.0000000000004356.","journal-title":"Ann Surg"},{"key":"2223_CR25","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1245\/s10434-013-2902-0","volume":"20","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Vald\u00e9s Olmos RA, Wesseling J, et al. Early assessment of axillary response with 18F-FDG PET\/CT during neoadjuvant chemotherapy in stage II\u2013III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20:2227\u201335. https:\/\/doi.org\/10.1245\/s10434-013-2902-0.","journal-title":"Ann Surg Oncol"},{"key":"2223_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ejrad.2009.03.051","volume":"70","author":"TD Poeppel","year":"2009","unstructured":"Poeppel TD, Krause BJ, Heusner TA, et al. PET\/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009;70:382\u201392. https:\/\/doi.org\/10.1016\/j.ejrad.2009.03.051.","journal-title":"Eur J Radiol"},{"key":"2223_CR27","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1007\/s00259-004-1536-7","volume":"31","author":"B Zangheri","year":"2004","unstructured":"Zangheri B, Messa C, Picchio M, et al. PET\/CT and breast cancer. Eur J Nucl Med Mol Imaging. 2004;31:S135\u201342. https:\/\/doi.org\/10.1007\/s00259-004-1536-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2223_CR28","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.1993.11.11.2101","volume":"11","author":"RL Wahl","year":"1993","unstructured":"Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101\u201311. https:\/\/doi.org\/10.1200\/JCO.1993.11.11.2101.","journal-title":"J Clin Oncol"},{"key":"2223_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-006-9159-2","volume":"98","author":"R Kumar","year":"2006","unstructured":"Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG\u2013PET in primary breast cancer. Breast Cancer Res Treat. 2006;98:267\u201374. https:\/\/doi.org\/10.1007\/s10549-006-9159-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2223_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.breast.2005.08.006","volume":"14","author":"G Viale","year":"2005","unstructured":"Viale G. Histopathology of primary breast cancer 2005. Breast. 2005;14:487\u201392. https:\/\/doi.org\/10.1016\/j.breast.2005.08.006.","journal-title":"Breast"},{"key":"2223_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10549-010-0771-9","volume":"123","author":"R Peare","year":"2010","unstructured":"Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat. 2010;123:281\u201390. https:\/\/doi.org\/10.1007\/s10549-010-0771-9.","journal-title":"Breast Cancer Res Treat"},{"key":"2223_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejso.2003.10.010","volume":"30","author":"G Zornoza","year":"2004","unstructured":"Zornoza G, Garcia-Velloso MJ, Sola J, et al. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol. 2004;30:15\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2003.10.010.","journal-title":"Eur J Surg Oncol"},{"key":"2223_CR33","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1200\/JCO.22.00503","volume":"40","author":"LA Korde","year":"2022","unstructured":"Korde LA, Somerfield MR, Hershman DL, Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline Expert Panel. Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40:1696\u20138. https:\/\/doi.org\/10.1200\/JCO.22.00503.","journal-title":"J Clin Oncol"},{"key":"2223_CR34","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-015-3070-1","volume":"42","author":"K Kitajima","year":"2015","unstructured":"Kitajima K, Fukushima K, Miyoshi Y, et al. Association between 18F-FDG uptake and molecular subtype of breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:1371\u20137. https:\/\/doi.org\/10.1007\/s00259-015-3070-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2223_CR35","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s00330-013-3037-1","volume":"24","author":"HR Koo","year":"2014","unstructured":"Koo HR, Park JS, Kang KW, et al. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol. 2014;24:610\u20138. https:\/\/doi.org\/10.1007\/s00330-013-3037-1.","journal-title":"Eur Radiol"},{"key":"2223_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-023-00953-y","volume":"13","author":"CM de Mooij","year":"2023","unstructured":"de Mooij CM, Ploumen RAW, Nelemans PJ, et al. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. EJNMMI Res. 2023;13:5. https:\/\/doi.org\/10.1186\/s13550-023-00953-y.","journal-title":"EJNMMI Res"},{"key":"2223_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3816\/CBC.2004.n.031","volume":"5","author":"RE Mansel","year":"2004","unstructured":"Mansel RE, Goyal A, Newcombe RG. Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience. Clin Breast Cancer. 2004;5:279\u201384. https:\/\/doi.org\/10.3816\/CBC.2004.n.031.","journal-title":"Clin Breast Cancer"},{"key":"2223_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-1464-0","volume":"15","author":"K Yang","year":"2020","unstructured":"Yang K, Kim H, Choi DH, et al. Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer. Radiat Oncol. 2020;15:16. https:\/\/doi.org\/10.1186\/s13014-020-1464-0.","journal-title":"Radiat Oncol"},{"key":"2223_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3857\/roj.2018.00451","volume":"37","author":"J Kim","year":"2019","unstructured":"Kim J, Chang JS, Choi SH, et al. Radiotherapy for initial clinically positive internal mammary nodes in breast cancer. Radiat Oncol J. 2019;37:91\u2013100. https:\/\/doi.org\/10.3857\/roj.2018.00451.","journal-title":"Radiat Oncol J"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02223-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:05:08Z","timestamp":1770894308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02223-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02223-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":". The study was approved by its institutional commission (20251107, Isala Lokale Haalbaarheid Commissie).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"46"}}